Abstract
Objective
investigate and compare the effect of valsartan and indapamide on inflammatory cytokines in hypertension.Methods
Forty-one untreated patients with mild to moderate hypertension and 20 age and sex-matched normotensives were enrolled in this study. Hypertensives were treated with indapamide 1.5 mg/d (n=20) or valsartan 80 mg/d (n=21) for 4 weeks, and blood samples for determining monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1 (MIP-1alpha), sP-selectin, asymmetric dimethylarginin (ADMA), angiotensin II (Ang II), and 6-keto-PGF1alpha were collected before the treatment and 4 weeks after the treatment.Results
Hypertensives exhibited significantly higher blood pressure, as well as elevated plasma levels of MCP-1, MIP-1alpha, sP-selectin and serum level of ADMA compared with the normotensives. Nevertheless, there was no significant difference in serum 6-keto-PGF1alpha and Ang II between the hypertensives and the normotensives. After the treatment with indapamide or valsartan for 4 weeks, both the systolic and diastolic blood pressures, though still higher than those of the normotensives, decreased markedly. After the treatment with indapamide for 4 weeks, MCP-1, MIP-1alpha and sP-selectin slightly decreased, but not statistically significant (P>0.05). Those cytokines decreased significantly after being treated with valsartan for 4 weeks [(19.16+/-3.11) pg/mL vs (16.08+/-2.67) pg/mL, P<0.05; (27.74+/-8.36) pg/mL vs (17.64+/-7.59) pg/mL, P<0.05; (2.67+/-3.18) pg/mL vs (6.15+/-2.94) pg/mL, P<0.01]. In the 2 treatment groups, 6-keto-PGF1alpha markedly increased [(61.96+/-20.81) pg/mL vs (96.72+/-25.89) pg/mL, P<0.05; (63.25+/-16.92) pg/mL vs (143.22+/-43.45) pg/mL, P<0.01]; ADMA decreased significantly [(1.35+/-0.74) pg/mL vs (0.98+/-0.56) micromol/L, P<0.05; (1.31+/-0.68) pg/mL vs (0.71+/-0.52) micromol/L, P<0.01]. Though Ang II slightly increased, no statistical significance was found (P>0.05).Conclusion
The levels of MCP-1, MIP-1alpha, sP-selectin and ADMA were elevated in mild to moderate hypertensives. Valsartan and indapamide have similar blood pressure lowering effect. Valasartan exerts more significant effect on cytokines than indapamide does.Citations & impact
Impact metrics
Citations of article over time
Article citations
Modulation of TNF-α, interleukin-6, and interleukin-10 by nebivolol-valsartan and nebivolol-lisinopril polytherapy in SHR rats.
Pharmacol Res Perspect, 12(2):e1189, 01 Apr 2024
Cited by: 4 articles | PMID: 38504425 | PMCID: PMC10951418
Immunomodulatory Activity of the Most Commonly Used Antihypertensive Drugs-Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers.
Int J Mol Sci, 23(3):1772, 04 Feb 2022
Cited by: 15 articles | PMID: 35163696 | PMCID: PMC8836033
Review Free full text in Europe PMC
Immunomodulatory Potential of Diuretics.
Biology (Basel), 10(12):1315, 11 Dec 2021
Cited by: 2 articles | PMID: 34943230 | PMCID: PMC8698805
Review Free full text in Europe PMC
The effect of valsartan and nebivolol treatment on ADMA and pentraxin-3 levels in hypertensive patients.
Med Hypotheses, 79(3):294-298, 13 Jun 2012
Cited by: 8 articles | PMID: 22698960
Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension.
Am J Physiol Regul Integr Comp Physiol, 296(2):R195-200, 06 Aug 2008
Cited by: 48 articles | PMID: 18685064 | PMCID: PMC2643983
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Effects of valsartan with or without benazepril on blood pressure, angiotensin II, and endoxin in patients with essential hypertension.
Acta Pharmacol Sin, 24(4):337-341, 01 Apr 2003
Cited by: 5 articles | PMID: 12676074
Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus.
Thromb Res, 117(4):385-392, 01 Jan 2006
Cited by: 57 articles | PMID: 15896827
Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, open-label, blinded end-point trial.
Clin Ther, 30(1):108-120, 01 Jan 2008
Cited by: 12 articles | PMID: 18343247
Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
Adv Ther, 25(4):300-320, 01 Apr 2008
Cited by: 13 articles | PMID: 18449492
Review